Cushing Disease Surgery Fails: What Are My Options?
At a Glance
When Cushing disease persists or returns after pituitary surgery, options include repeat surgery, cortisol-lowering medicine, focused radiation, or bilateral adrenalectomy. The choice depends on MRI findings, how urgently cortisol must be controlled, and the risk of lifelong hormone replacement.
It can be incredibly disheartening to learn that your first transsphenoidal surgery (TSS)—surgery performed through the nose to remove a pituitary tumor—did not completely cure your Cushing’s disease. However, additional effective treatments are available, although the chance and speed of control vary [1][2].
Before deciding on a next step, your endocrinologist will use blood, urine, or saliva tests to confirm whether your hypercortisolism (excess cortisol) is truly active [2]. If your cortisol remains high immediately after surgery, you have persistent disease; if it normalized but later became high again, you have recurrent disease [2]. The goal of any subsequent treatment is to achieve biochemical control—meaning your cortisol test results return to the normal, healthy target range [3].
Because every patient is different, your care should be managed by a multidisciplinary pituitary team [1]. They will typically consider four main treatment paths, often used in combination.
1. Repeat Pituitary Surgery
If your team can identify a clear, visible piece of the residual or recurrent tumor on a high-quality pituitary MRI, a second surgery is often discussed as a next step [1][4].
- Success Rates: When performed by a highly experienced pituitary surgeon, studies show repeat surgery achieves remission in roughly 65% of cases [5][6]. The best outcomes occur when the remaining tumor is a microadenoma (a very small tumor) and is safely accessible [7].
- Considerations and Risks: A second operation carries higher risks than the first. For example, the chance of temporary diabetes insipidus (a condition causing extreme thirst and heavy urination) is roughly 38%, compared to about 13% for first-time surgeries [8]. Other risks include permanent hypopituitarism (loss of normal pituitary hormones), cerebrospinal fluid (CSF) leaks, and rare visual or vascular injuries [8][9]. If the surgery is successful, you will likely experience temporary adrenal insufficiency and need glucocorticoid pills until your normal pituitary gland recovers [8].
2. Medical Therapy (Cortisol-Lowering Medications)
If a second surgery is not possible, or if you need to lower your cortisol while waiting for radiation to work, your doctor may prescribe medication [3][10]. While these drugs generally do not cure the underlying tumor, they can dramatically improve your health by normalizing your cortisol levels.
- Adrenal-directed medications: Drugs like osilodrostat, ketoconazole, metyrapone, and levoketoconazole block the adrenal glands from producing cortisol [3]. Osilodrostat is highly effective, rapidly normalizing urinary free cortisol (UFC) in roughly 77% of patients within 12 weeks [11][12]. Ketoconazole acts quickly but requires careful liver monitoring [13]. Risks for these drugs include dropping cortisol too low (hypocortisolism), potassium changes, and heart rhythm (QT interval) effects [14][15].
- Pituitary-directed medications: Pasireotide and cabergoline target the pituitary tumor itself to reduce the production of ACTH (the hormone that tells your adrenal glands to make cortisol) [3][16]. Pasireotide works well for a specific subgroup of patients but frequently causes or worsens high blood sugar [17].
- Glucocorticoid-receptor antagonists: Medications like mifepristone block cortisol from affecting your body’s tissues [3]. Because it does not lower the actual amount of cortisol in your blood, its effectiveness must be monitored by tracking your physical symptoms rather than traditional lab tests [3].
Note: Any highly effective cortisol-lowering drug can temporarily oversuppress your system, leading to adrenal insufficiency. You will be monitored closely; never change your dose without medical supervision.
3. Targeted Pituitary Radiation
Stereotactic radiosurgery (such as Gamma Knife) uses focused beams of radiation to target the residual pituitary tumor [18].
- Efficacy and Timeline: Radiation successfully stops tumor growth in over 85% of cases and eventually normalizes cortisol levels in 70% to 80% of patients [19][18]. However, the effects are delayed. It takes an average of 14 to 15 months (and sometimes much longer) for cortisol levels to normalize, so you will need bridging medications in the meantime [18][20].
- Side Effects: While radiation aims to target the tumor, nearby healthy tissue can be affected [21]. Up to 31% of patients develop delayed hypopituitarism within 10 years, requiring lifelong hormone surveillance [22]. Visual injuries or secondary brain tumors are extremely uncommon (0–5%) but remain a possibility, especially if the tumor is very close to the optic nerves [18][21].
4. Bilateral Adrenalectomy
Bilateral adrenalectomy is the surgical removal of both adrenal glands. It is generally considered when hypercortisolism is severe, rapidly progressive, or when other treatments fail or are unsuitable [23][24].
- The Results: This surgery stops adrenal cortisol production entirely, providing rapid and definitive control of the cortisol excess [23][25]. Clinical symptoms improve gradually as your body heals. Research indicates a surgical complication rate of around 15% [25].
- Lifelong Adrenal Insufficiency: Without adrenal glands, you will permanently have zero natural cortisol [26]. You must take daily replacement hormones (hydrocortisone and fludrocortisone) for the rest of your life [26].
- Adrenal Crisis Safety: You will be at permanent risk for a life-threatening adrenal crisis. You must have an individualized emergency plan, wear a medical-alert ID, and learn “sick-day rules” (such as doubling or tripling your pill dose when ill) [26]. If you are vomiting and cannot keep pills down, or experience severe weakness, confusion, or fainting, you must use an emergency steroid injection and seek immediate medical care [26][23].
- Nelson Syndrome: Because the adrenal glands are gone but the pituitary tumor remains, the tumor can grow aggressively and produce very high levels of ACTH—a condition called Nelson syndrome [27]. Regular lifelong monitoring with pituitary MRIs and ACTH blood tests is required to detect this [27][28].
Summary of Second-Line Options
| Treatment Option | Primary Target | Speed of Cortisol Control | Potential for Lifelong Replacement Therapy? |
|---|---|---|---|
| Repeat Surgery | Pituitary Tumor | Fast | Yes, if normal pituitary tissue is damaged. |
| Medication | Varies (Adrenal or Pituitary) | Fast to Moderate | Temporary, if doses oversuppress cortisol. |
| Radiation | Pituitary Tumor | Slow (Months to Years) | Yes, risk increases steadily over time. |
| Bilateral Adrenalectomy | Adrenal Glands | Fast | Yes, 100% guaranteed (Requires sick-day plan). |
Living with persistent or recurrent Cushing’s disease is physically and emotionally demanding. Your care team will work closely with you to manage your symptoms, balance the trade-offs of each treatment, and find the safest path to sustained control.
Common questions in this guide
How can I tell whether Cushing disease is still active after surgery?
Could a second pituitary operation cure Cushing disease?
Which medicines can lower cortisol after pituitary surgery does not work?
How long does radiation take to control Cushing disease?
What happens if I have both adrenal glands removed?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Do my latest lab results and MRI confirm active disease, and is there a clearly visible, safely reachable tumor target for a second surgery?
- 2.What are the specific risks of a second surgery for my case, and how does your center's success rate compare to national averages?
- 3.If we decide to use medication to lower my cortisol, which drug best fits my specific health profile, considering my blood sugar, liver function, and heart health?
- 4.If we choose radiation therapy, what is our 'bridge' plan to manage my cortisol levels and symptoms during the months or years it takes to work?
- 5.If we proceed with bilateral adrenalectomy, will I be provided with formal training on sick-day rules and how to self-administer an emergency steroid injection?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (28)
- 1
A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism.
Machado MC, Fragoso MCBV, Moreira AC, et al.
Archives of endocrinology and metabolism 2018; (62(1)):87-105 doi:10.20945/2359-3997000000014.
PMID: 29694638 - 2
An individualized approach to the management of Cushing disease.
Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, et al.
Nature reviews. Endocrinology 2023; (19(10)):581-599 doi:10.1038/s41574-023-00868-7.
PMID: 37537306 - 3
The Treatment of Cushing's Disease.
Pivonello R, De Leo M, Cozzolino A, Colao A
Endocrine reviews 2015; (36(4)):385-486 doi:10.1210/er.2013-1048.
PMID: 26067718 - 4
Outcome of Microscopic Transsphenoidal Surgery in Cushing Disease: A Case Series of 96 Patients.
Shirvani M, Motiei-Langroudi R, Sadeghian H
World neurosurgery 2016; (87()):170-5.
PMID: 26704208 - 5
Recurrent Cushing Disease: An Extensive Review on Pros and Cons of Different Therapeutic Approaches.
Sabahi M, Ghasemi-Nesari P, Maroufi SF, et al.
World neurosurgery 2023; (172()):49-65 doi:10.1016/j.wneu.2023.01.108.
PMID: 36739900 - 6
Outcomes After Repeat Transsphenoidal Surgery for Recurrent Cushing Disease: Updated.
Burke WT, Penn DL, Repetti CS, et al.
Neurosurgery 2019; (85(6)):E1030-E1036 doi:10.1093/neuros/nyz193.
PMID: 31140553 - 7
Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series.
Serban AL, Del Sindaco G, Sala E, et al.
Journal of endocrinological investigation 2020; (43(5)):631-639 doi:10.1007/s40618-019-01151-1.
PMID: 31773581 - 8
Complications after transsphenoidal surgery for patients with Cushing's disease and silent corticotroph adenomas.
Smith TR, Hulou MM, Huang KT, et al.
Neurosurgical focus 2015; (38(2)):E12 doi:10.3171/2014.10.FOCUS14705.
PMID: 25639314 - 9
Surgical and radiosurgical treatment strategies for Cushing's disease.
Bunevicius A, Laws ER, Vance ML, et al.
Journal of neuro-oncology 2019; (145(3)):403-413 doi:10.1007/s11060-019-03325-6.
PMID: 31677031 - 10
Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome.
Araujo-Castro M, Lamas C, Nowak E, et al.
Endocrine reviews 2026; (47(3)):301-328 doi:10.1210/endrev/bnaf042.
PMID: 41489578 - 11
Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
Gadelha M, Bex M, Feelders RA, et al.
The Journal of clinical endocrinology and metabolism 2022; (107(7)):e2882-e2895 doi:10.1210/clinem/dgac178.
PMID: 35325149 - 12
Individualized osilodrostat treatment for patients with ACTH-dependent Cushing's syndrome: real-world evidence.
Gilis-Januszewska A, Gamrat-Żmuda A, Minasyan M, et al.
Frontiers in endocrinology 2026; (17()):1866631 doi:10.3389/fendo.2026.1866631.
PMID: 42500126 - 13
Adrenally Directed Medical Therapies for Cushing Syndrome.
Tritos NA
The Journal of clinical endocrinology and metabolism 2021; (106(1)):16-25 doi:10.1210/clinem/dgaa778.
PMID: 33118025 - 14
Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
Dougherty JA, Desai DS, Herrera JB
The Annals of pharmacotherapy 2021; (55(8)):1050-1060 doi:10.1177/1060028020968808.
PMID: 33143437 - 15
Osilodrostat: A Review of Recent Clinical Studies and Practical Recommendations for its Use in the Treatment of Cushing Disease.
Yuen KCJ
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2021; (27(9)):956-965 doi:10.1016/j.eprac.2021.06.012.
PMID: 34389514 - 16
Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis.
Palui R, Sahoo J, Kamalanathan S, et al.
Journal of endocrinological investigation 2018; (41(12)):1445-1455 doi:10.1007/s40618-018-0936-7.
PMID: 30097903 - 17
Tumor-Directed Therapeutic Targets in Cushing Disease.
Theodoropoulou M, Reincke M
The Journal of clinical endocrinology and metabolism 2019; (104(3)):925-933 doi:10.1210/jc.2018-02080.
PMID: 30535260 - 18
Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study.
Mehta GU, Ding D, Patibandla MR, et al.
The Journal of clinical endocrinology and metabolism 2017; (102(11)):4284-4291 doi:10.1210/jc.2017-01385.
PMID: 28938462 - 19
Technique of Whole-Sellar Stereotactic Radiosurgery for Cushing Disease: Results from a Multicenter, International Cohort Study.
Shepard MJ, Mehta GU, Xu Z, et al.
World neurosurgery 2018; (116()):e670-e679 doi:10.1016/j.wneu.2018.05.067.
PMID: 29783006 - 20
Radiosurgical Management of Patients With Persistent or Recurrent Cushing Disease After Prior Transsphenoidal Surgery: A Management Algorithm Based on a 25-Year Experience.
Hughes JD, Young WF, Chang AY, et al.
Neurosurgery 2020; (86(4)):557-564 doi:10.1093/neuros/nyz159.
PMID: 31140563 - 21
STEREOTACTIC RADIATION THERAPY IN PITUITARY ADENOMAS, IS IT BETTER THAN CONVENTIONAL RADIATION THERAPY?
Gheorghiu ML, Fleseriu M
Acta endocrinologica (Bucharest, Romania : 2005) 2017; (13(4)):476-490 doi:10.4183/aeb.2017.476.
PMID: 31149219 - 22
Hypopituitarism after Gamma Knife radiosurgery for pituitary adenomas: a multicenter, international study.
Cordeiro D, Xu Z, Mehta GU, et al.
Journal of neurosurgery 2019; (131(4)):1188-1196 doi:10.3171/2018.5.JNS18509.
PMID: 31369225 - 23
A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome.
Reincke M, Ritzel K, Oßwald A, et al.
European journal of endocrinology 2015; (173(4)):M23-32 doi:10.1530/EJE-15-0265.
PMID: 25994948 - 24
The role of bilateral adrenalectomy in the treatment of refractory Cushing's disease.
Wong A, Eloy JA, Liu JK
Neurosurgical focus 2015; (38(2)):E9 doi:10.3171/2014.10.FOCUS14684.
PMID: 25639327 - 25
Synchronous bilateral adrenalectomy in ACTH-dependent hypercortisolism: predictors, biomarkers and outcomes.
Chiloiro S, Giampietro A, Raffaelli M, et al.
Endocrine 2019; (66(3)):642-649 doi:10.1007/s12020-019-02091-9.
PMID: 31583577 - 26
Cyclical ectopic Cushing's syndrome due to a mediastinal neuroendocrine tumor: a case-based review.
Peixe C, Lopes MV, de Griné Severino M, et al.
Irish journal of medical science 2026; doi:10.1007/s11845-026-04432-w.
PMID: 42126756 - 27
Stereotactic radiosurgery before bilateral adrenalectomy is associated with lowered risk of Nelson's syndrome in refractory Cushing's disease patients.
Bunevicius A, Lavezzo K, Smith PW, et al.
Acta neurochirurgica 2021; (163(7)):1949-1956 doi:10.1007/s00701-021-04823-1.
PMID: 33759014 - 28
[Nelson's Syndrome].
Krysiak R, Kędzia A, Okopień B
Wiadomosci lekarskie (Warsaw, Poland : 1960) 2015; (68(3 pt 2)):393-401.
PMID: 28501841
This page is for informational purposes only and does not constitute medical advice about treatment after Cushing disease surgery. Your endocrinologist and pituitary team should confirm active disease and recommend the safest option for your situation.
Get notified when new evidence is published on Cushing disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.